Bayer’s Triple Catalyst Summer: A Supreme Court Ruling, a $7.25 Billion Settlement Hearing, and a $2.45 Billion Glaucoma Gambit

Bayer's stock hangs on US Supreme Court glyphosate decision and Missouri settlement approval, with a $2.45B glaucoma drug bet and mounting debt risks.

The next two weeks will define Bayer’s trajectory more than any quarterly report. By the end of June, the US Supreme Court is expected to hand down its decision in the Durnell glyphosate case. Barely a week later, on July 9, a federal judge in Missouri will hold the final hearing to approve or reject the company’s $7.25 billion roundup settlement. Between those two events, Bayer also faces a trade probe in Washington and is simultaneously betting $2.45 billion on an early-stage glaucoma drug. The stock, currently changing hands at around €38, has clawed back nearly 6% in the past seven days, but it remains 24% below its 52-week high of €50.

The Durnell Decision: A Knife That Cuts Both Ways

If the Supreme Court rules in Bayer’s favor, the impact would be seismic. The case asks whether a federal agency’s safety label can preempt state-level claims — and a win would effectively neutralise roughly 65,000 pending glyphosate lawsuits. UBS analyst Matthew Weston puts the probability of such an outcome at 70%. That would free up billions in cash currently being drained by litigation. Bayer has already paid more than $10 billion to settle roundup claims, and the Q1 2026 free cash flow was a haemorrhaging minus €2.3 billion, worsening from minus €1.5 billion a year earlier.

A loss, however, would send the stock straight back to the 200-day moving average at €36.27 and refocus attention on the company’s towering net debt of €32.5 billion at the end of March. The debt pile is expected to swell to around €33 billion by year-end, and management has warned of a negative cash flow of up to €2.5 billion for 2026.

Missouri’s July 9 Hearing: Objections Are Already Mounting

Independently of the Supreme Court, the Missouri settlement venue is attracting its own risks. Lawyers representing some plaintiffs formally objected in late May, arguing the deal is unfair and inadequate. Should too many claimants opt out, Bayer has the right to walk away from the entire agreement. The hearing on July 9 will decide whether the settlement class is certified. If it is, the litigation costs that have been bleeding the balance sheet could finally be capped. If not, the cash drain will continue.

A $2.45 Billion Bet on a Single Molecule

While the legal calendar dominates investor attention, Bayer has been quietly deploying capital. On June 17, the group completed the acquisition of Perfuse Therapeutics for $300 million upfront, with milestone payments that could push the total to $2.45 billion. The prize is PER-001, a novel endothelin receptor blocker in Phase II trials for glaucoma. No drug in that class has ever been approved for an eye indication. If it succeeds, PER-001 could offset the looming patent losses on Eylea and Xarelto. But Phase II candidates frequently fail, and a launch remains years away.

Operationally, the company argues that its pipeline is gaining traction. Q1 2026 net revenue rose to €13.4 billion on a currency-adjusted basis, while operating profit reached roughly €4.45 billion. The crop science division started the year strongly, with organic seed sales up 6.8%. In pharmaceuticals, new drugs Nubeqa and Kerendia are already delivering meaningful revenue growth, and the FDA is reviewing a sped-up approval for the anticoagulant asundexian, with a decision expected in the second half of 2026.

Washington Adds Another Layer of Uncertainty

Not all the drama is in the courts. The Office of the US Trade Representative is examining German drug-pricing regulations, and the worst-case scenario — retaliatory tariffs on German pharmaceuticals — would directly hit Bayer’s top line. Barclays analysts have also flagged procedural delays in the Missouri settlement process, warning that open questions about jurisdiction could push key hearings into the autumn.

What the Next Two Weeks Will Deliver

For now, Bayer stock is trading as a pure binary wager on the next two legal milestones. If the Supreme Court rules in its favour, the narrative flips instantly from litigation risk to debt-deleveraging and pipeline strength. If not, the cash flow gap and the debt mountain will dominate until at least the July 9 hearing, and possibly beyond. The stock’s current premium above its 50-day moving average of €37.76 is fragile. The next real catalyst is a verdict, not a spreadsheet.